NPM1 and acute myeloid leukemia: The presence of adverse-risk cytogenetic abnormalities in NPM1-mutated AML is classified as being an adverse risk16,17, and additional disease-defining recurring cytogenetic abnormalities, including t(3q26.2;v) and t(8;16)(p11.2;p13.3) were included in the adverse risk group18.